Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Srinivas AkkarajuDirector | Kalaris TherapeuticsKLRS | Open-market buy | 05/20 | 05/22 | 244,300 sh | $4.83 | $1,179,969 | +12.3% |
Samsara BioCapital10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 05/20 | 05/22 | 244,300 sh | $4.83 | $1,179,969 | +12.3% |
Samsara BioCapital GP10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 05/20 | 05/22 | 244,300 sh | $4.83 | $1,179,969 | +12.3% |
Samsara Opportunity Fund10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 05/20 | 05/22 | 244,300 sh | $4.83 | $1,179,969 | +12.3% |
Samsara Opportunity Fund GP10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 05/20 | 05/22 | 244,300 sh | $4.83 | $1,179,969 | +12.3% |
Hagen Brett R.Chief Accounting Officer | Kalaris TherapeuticsKLRS | Open-market sale | 03/20 | 03/23 | 1,915 sh | $6.72 | $12,868.8 | −100.0% |
Srinivas AkkarajuDirector | Kalaris TherapeuticsKLRS | Open-market buy | 25/12/18 | 02/17 | 479,847 sh | $10.42 | $5,000,005.74 | +32.0% |
Samsara BioCapital10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 25/12/18 | 02/17 | 479,847 sh | $10.42 | $5,000,005.74 | +32.0% |
Samsara BioCapital GP10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 25/12/18 | 02/17 | 479,847 sh | $10.42 | $5,000,005.74 | +32.0% |
Samsara Opportunity Fund10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 25/12/18 | 02/17 | 479,847 sh | $10.42 | $5,000,005.74 | +32.0% |
Samsara Opportunity Fund GP10% Owner | Kalaris TherapeuticsKLRS | Open-market buy | 25/12/18 | 02/17 | 479,847 sh | $10.42 | $5,000,005.74 | +32.0% |
Hagen Brett R.Chief Accounting Officer | Kalaris TherapeuticsKLRS | Open-market sale | 25/03/26 | 25/03/27 | 907 sh | $8.97 | $8,135.79 | −32.0% |